Healthy adults
Conditions
Interventions
Single ingestion of decaffeinated green coffee bean extract powder with high-fat meal, and take washout period for 1 week, and then, single ingestion of placebo powder with high-fat meal.
Single inges
Sponsors
Hokkaido Information University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects who fully understand significance, content and purpose of this study and who agree to participate in this study with a written informed consent. 2. Subjects whose fasting serum triglyceride levels are 100 mg/dl or more and 149 mg/dl or less. 3. Subjects with relatively high postprandial serum triglyceride levels.
Exclusion criteria
Exclusion criteria: 1. Subjects who are under physician's advice, treatment, and/or medication for dyslipidemia and/or diabetes. 2. Subjects with familial hypercholesterolemia. 3. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 4. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 5. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 6. Subjects with severe anemia. 7. Pre- or post-menopausal women complaining of obvious physical changes. 8. Subjects who experienced unpleasant feeling during drawing blood in the past. 9. Subjects who are at risk of having allergic reactions to drugs or foods especially based on coffee, milk, egg, wheat, shrimp, soybean, chicken and/or pork. 10. Subjects with lactose intolerance. 11. Subjects who regularly take medicine, functional foods, and/or supplements which would affect lipid metabolism. 12. Subjects who regularly take medicine, functional foods, and/or supplements which would affect glucose metabolism. 13. Heavy smokers, alcohol addicts or subjects with disordered lifestyle. 14. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the screening tests. 15. Pregnant or lactating women or women who expect to be pregnant during this study. 16. Subjects who currently participate in other clinical trials, or participate within the last 4 weeks prior to the study. 17. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Delta TG, incremental area under the curve (iAUC) of TG (0 to 6 hours) | — |
Secondary
| Measure | Time frame |
|---|---|
| TG, area under the curve (AUC) of TG, RLP-C, delta RLP-C, AUC of RLP-C, iAUC of RLP-C, NEFA, delta NEFA, AUC of NEFA, iAUC of NEFA, blood glucose, delta blood glucose, AUC of blood glucose, iAUC of blood glucose, insulin, delta insulin, AUC of insulin, iAUC of insulin (0 to 6 hours) | — |
Countries
Japan
Contacts
Public ContactNaoyuki HONMA
Hokkaido Information University Health Information Science Center
Outcome results
None listed